BioSpace News Archive

Global Center for Medical Innovation, the Southeast’s first and only comprehensive medical device innovation center, announced a collaboration that addresses the severe shortage of personal protective equipment for protecting the nation’s hospital workers from the COVID-19 pandemic.

As part of the U.S. Food and Drug Administration’s ongoing commitment to combatting the coronavirus pandemic and providing flexibility across FDA-regulated industries, the agency announced that it intends to temporarily not enforce certain requirements in order to allow veterinarians to better utilize telemedicine to address animal health needs during the pandemic.

Cell>Point announced today its plans to move forward with its research program to clinically develop 99mTc-EC-Amifostine and 177Lu-EC-Amifostine to assess, treat and follow-up with confirmatory imaging for people who contract COVID-19.

As lawmakers hurry to finalize a legislative package responding to the coronavirus pandemic, the U.S. Conference of Mayors is urging them to ensure a greater number of cities are eligible for federal resources.

Bright and early Monday morning, Hoth Therapeutics, Inc. released news that the Company had entered into a joint venture agreement with its joint venture partner, Voltron Therapeutics, Inc., for the “Joint Development for a Self-Assembling Vaccine for the Potential Prevention of the Coronavirus.”.

As Minnesota dentists follow a mandate by the Governor’s Office to temporarily suspend non-emergent and elective procedures in order to lessen transmission of COVID-19, many dentists remain available to provide emergency care – and they urge people to seek that care by contacting a dentist if they need it.

CEL-SCI Corporation announced today that, due to demand, the underwriter has agreed to increase the size of its previously announced offering and purchase on a firm commitment basis 630,500 shares of common stock of the Company, at a price to the public of $12.22 per share (the “Public Price”), representing a 5% discount to the closing price per share. The

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited (Hong Kong Stock Exchange: 2181HK, “Mabpharm”), for the clinical development and commercialization of the ACE-MAB fusion protein

Stryker (NYSE:SYK) announced its 2020 Annual Meeting of Shareholders is scheduled as follows:

The Edison Awards announced Zsquare as winners of the silver award in the Medical/Dental category alongside finalists Boston Scientific and Zimmer Biomet.